Medtronic PulseSelect system shows 100% acute success rate in AFib registry study

• Medtronic announced positive real-world registry results for its Sphere-9 catheter and PulseSelect ablation system, presented at APHRS 2026.
• The APEX registry found low major complication rates with Sphere-9 in atrial fibrillation patients, with similar safety across initial and repeat procedures.
• The REAL PULSE registry showed strong immediate procedural success with PulseSelect in atrial fibrillation patients, with few major complications.
• A separate APEX analysis showed promising ventricular tachycardia control with Sphere-9, though major complications occurred in some patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: CG78679) on October 22, 2026, and is solely responsible for the information contained therein.